Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia

Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase 3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)

(2021) Matthew G. Johnson et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

(2021) James A. Karlowsky et al.   BMC MICROBIOLOGY

Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections

(2021) Laura Puzniak et al.   Infectious Diseases and Therapy

Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017

(2020) Jean-Louis Vincent et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia

(2020) Luzelena Caro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial

(2020) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of the in vitro susceptibility of ceftolozane-tazobactam to the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aeruginosa from ICU patients with bloodstream infections or pneumonia

(2019) Dee Shortridge et al.   Open Forum Infectious Diseases

Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world

(2019) Jason M. Pogue et al.   EXPERT OPINION ON PHARMACOTHERAPY

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

(2019) Marin H Kollef et al.   LANCET INFECTIOUS DISEASES

In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)

(2019) James A. Karlowsky et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program

(2019) Dee Shortridge et al.   Journal of Global Antimicrobial Resistance

Culture-Negative Septic Shock Compared With Culture-Positive Septic Shock

(2018) Shravan Kethireddy et al.   CRITICAL CARE MEDICINE

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program

(2018) Dee Shortridge et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance

(2018) Patrick N. A. Harris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17)

(2018) Helio S Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparing current US and European guidelines for nosocomial pneumonia

(2018) Daire N. Kelly et al.   CURRENT OPINION IN PULMONARY MEDICINE

Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers

(2018) Cecilia G. Carvalhaes et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

(2018) George H Talbot et al.   JOURNAL OF INFECTIOUS DISEASES

The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections

(2018) Hiroshige Mikamo et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs

(2017) B. Borgatta et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia

(2017) Antoni Torres et al.   EUROPEAN RESPIRATORY JOURNAL

How Should We Treat Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae?

(2017) Jean-François Timsit et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module

(2016) Víctor Daniel Rosenthal et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014

(2016) Lindsey M. Weiner et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

(2015) Joseph Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia

(2015) Alan J. Xiao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

(2015) Florian M Wagenlehner et al.   LANCET

Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management

(2015) Keith S. Kaye et al.   PHARMACOTHERAPY

The impact of multidrug resistance on outcomes in ventilator-associated pneumonia

(2014) Rudy Tedja et al.   AMERICAN JOURNAL OF INFECTION CONTROL

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

(2014) Víctor Daniel Rosenthal et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012

(2014) Helio S. Sader et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies

(2013) Wilhelmina G Melsen et al.   LANCET INFECTIOUS DISEASES

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

(2012) G. Chandorkar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

(2010) Ronald N. Jones   CLINICAL INFECTIOUS DISEASES

Antimicrobial Therapy for Life-threatening Infections: Speed is Life

(2010) Duane J. Funk et al.   CRITICAL CARE CLINICS

Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock

(2009) Anand Kumar et al.   CHEST